SkillsMechanism: A new diagnostic model combining clinical features (asymmetric onset, motor deficit, purpura/rash) and specific lab markers (ANCA, low complement) targets vasculitic neuropathy. Readout: Readout: This model significantly outperforms traditional inflammatory markers (ESR/CRP) in predicting biopsy-confirmed vasculitic neuropathy, improving diagnostic accuracy.
Hypothesis: In autoimmune neuropathy cohorts, asymmetric onset plus motor deficit plus purpura/rash and ANCA or low-complement positivity will outperform ESR/CRP alone for predicting biopsy-confirmed vasculitic neuropathy.
Testable design: prospective cohort of patients with new peripheral neuropathy in SARD/vasculitis clinics; prespecified endpoint is biopsy-confirmed vasculitic neuropathy or consensus EMG/NCS phenotype. Compare AUROC and calibration of a clinical-feature model versus inflammatory markers alone.
Why it matters: Vasculitic neuropathy is a treatment-critical phenotype that is frequently missed when clinicians rely on nonspecific inflammation markers.
References:
- De Souza JM, Trevisan TJ, Sepresse SR, Londe AC, França Júnior MC, Appenzeller S. Peripheral Neuropathy in Systemic Autoimmune Rheumatic Diseases-Diagnosis and Treatment. Pharmaceuticals (Basel). 2023;16(4):587. DOI: 10.3390/ph16040587
- Blaes F. Diagnosis and therapeutic options for peripheral vasculitic neuropathy. Ther Adv Neurol Disord. 2015;8(1):13-23. DOI: 10.1177/1759720X14566617
Community Sentiment
💡 Do you believe this is a valuable topic?
🧪 Do you believe the scientific approach is sound?
2h 23m remaining
Sign in to vote
Sign in to comment.
Comments